ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 504

Raynaud’s Phenomenon and African American Race Are Independently Associated With Non-Hodgkin’s Lymphoma In Sjogrens Syndrome Patients: Findings From a United States National Study

Bella Mehta1, Neville Jadeja2, Marjan Mujib3 and Petros V. Efthimiou4, 1Internal Medicine, Westchester Medical Center at New York Medical College, valhalla, NY, 2Internal Medicine, Jacobi Medical Center, New York, NY, 3Internal Medicine, New York Medical College, Valhalla, NY, 4Medicine/Rheumatology, LM&MHC/Weill Cornell MC, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Raynaud's phenomenon and Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome: Clinical Aspects

Session Type: Abstract Submissions (ACR)

Background/Purpose: ,

Higher incidence of lymphoma in sjogrens syndrome has been reported since more than 5 decades now. Non Hodgkin’s Lymphoma (NHL) ranks as the seventh leading cause of cancer diagnosis in United States. There are numerous reports of Raynaud’s syndrome being an early paraneoplastic manifestation of occult malignancies.

Objectives:

To investigate the associations of  rheumatologic and immunologic conditions with NHL  in hospitalized patients with Sjogrens disease from a large nationwide hospital registry database.

Methods:

All hospitalized patients  included in the nationwide inpatient sample (NIS) 2010 database with a confirmed discharge diagnosis of Sjogrens disease, as per the ICD-9-CM code 710.2 were identified. NIS is the largest all-payer inpatient care database in the United States. Multivariable logistic regression models were used to determine the associations of rheumatic diseases and demographics of the population with Non-Hodgkin’s lymphoma among these patients. Discharge weight was used to measure national estimates.

Results:

From 7,800,441 hospitalizations in NIS 2010 database, 7,734 sjogrens syndrome patients were identified. Patients had a mean age of 63.47 (±16.03) years, 91.14% (7,049) were women. We used weighted analysis to estimate the national values. 38677 sjogrens syndrome patients were thus analyzed. 34923(90.29%)  had no NHL or Raynaud’s, 758 (1.96%) had no Raynaud’s but had NHL. 2843 (7.35%) had Raynaud’s present but no NHL. 153(0.4%) had both NHL and Raynaud’s. Models were adjusted for Age, Sex, Vasculitis, Systemic Lupus Erythematosus, HIV, Rheumatoid Arthritis, Dermatmyosisits, Polymyositis, Connective tissue disease, Polymyalgia Rheumatica, Systemic sclerosis, Celiac Disease, Hypthyroidism, Autoimmune hepatitis, Hepatitis C virus infection, Smoking history and African American race. African american race was independently associated with presence of NHL(adjusted odds ratio, 2.217; 95% confidence interval, 1.791 – 2.745 ; p<0.005)   Raynaud's syndrome was found to be independently associated with NHL (adjusted odds ratio, 2.854 ; 95% confidence interval, 2.357 – 3.456 ; p<0.005).(Table 1)

Conclusion:

In this large national database, African american race and Raynaud’s syndrome was independently associated with non-hodgkins lymphoma among hospitalized sjogrens patients. The presence of Raynaud’s syndrome  in patients with Sjogren’s should arouse  clinical suspicion for this feared complication.  Further prospective studies and are needed to understand this relationship in this high-risk population.

Table 1:

CHARACTERISTICS

Adjusted Odds Ratio

95% C.I.for OR

P Value

Lower

Upper

AGE

1.010

1.006

1.015

.000

SEX(FEMALE)

1.330

1.080

1.638

.007

AFRICAN AMERICAN

2.217

1.791

2.745

.000

SLE

.716

.588

.873

.001

RHEUMATIOD ARTHRITIS

0.335

0.265

0.423

.000

RAYNAUD’S

2.854

2.357

3.456

.000

VASCULITIS

1.684

1.139

2.490

.009

POLYMYOSITIS

3.606

2.172

5.987

.000

CONNECTIVE TISSUE DISEASE

1.274

.671

2.418

.458

SYSTEMIC SCLEROSIS

0.866

0.618

1.214

.405

CELIAC DISEASE

2.203

1.313

3.695

.003

HYPOTYROIDISM

.753

.636

0.893

.001

AUTOIMMUNE HEPATITIS

0.999

.516

1.935

.997

HEPATITIS C VIRUS

1.402

.573

3.430

.459

SMOKING HISTORY

0.227

0.124

0.416

.000


Disclosure:

B. Mehta,
None;

N. Jadeja,
None;

M. Mujib,
None;

P. V. Efthimiou,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/raynauds-phenomenon-and-african-american-race-are-independently-associated-with-non-hodgkins-lymphoma-in-sjogrens-syndrome-patients-findings-from-a-united-states-national-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology